This thread is getting painful. There are legit aducanumab comparisons that point to the potential value of a cognition/Alzheimer's drug based on how much Biogen's market cap dropped after their failed trial and the notion that apabetalone could be worth similar if it proves effective in cognitive diseases. There are legit humira comparisons based on the number of indications that humira is used for and the notion that apabetalone could potentially treat many diseases beyond just cardio, renal and cognition... including but not limited to various diseases with an inflammation component.

BearDownAZ